RheeCDantesREpsteinL, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017;318(13):1241-1249. doi:10.1001/jama.2017.13836
2.
RuddKEJohnsonSCAgesaKM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
3.
SingerMDeutschmanCSSeymourCW, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287
WolfeCRTomashekKMPattersonTF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10(9):888-899. doi:10.1016/S2213-2600(22)00088-1
6.
KotchCBarrettDTeacheyDT.Tocilizumab for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813-822. doi:10.1080/1744666X.2019.1629904
7.
ZumlaARaoMWallisRS, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016;16(4):e47-e63. doi:10.1016/S1473-3099(16)00078-5
8.
BodeCWeisSSauerAWendel-GarciaPDavidS.Targeting the host response in sepsis: current approaches and future evidence. Crit Care. 2023;27(1):478. doi:10.1186/s13054-023-04762-6
9.
VincentJLvan der PollTMarshallJC.The end of “one size fits all” sepsis therapies: toward an individualized approach. Biomedicines. 2022;10(9):2260. doi:10.3390/biomedicines10092260
10.
GardunoACusackRLeoneMEinavSMartin-LoechesI.Multi-omics endotypes in ICU sepsis-induced immunosuppression. Microorganisms. 2023;11(5):1119. doi:10.3390/microorganisms11051119
FinkMP.Animal models of sepsis. Virulence. 2014;5(1):143-153. doi:10.4161/viru.26083
13.
OsuchowskiMFAyalaABahramiS, et al. Minimum Quality Threshold in Pre-clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Intensive Care Med Exp. 2018;6(1):26. doi:10.1186/s40635-018-0189-y
14.
StrichJRRamos-BenitezMJWarnerS, et al. Klebsiella pneumoniae induces dose-dependent shock, organ dysfunction, and coagulopathy in a nonhuman primate critical care model. mBio. 2025;16(1):e0194324. doi:10.1128/mbio.01943-24
15.
GrimaldiDVincentJL.Clinical trial research in focus: rethinking trials in sepsis. Lancet Respir Med. 2017;5(8):610-611. doi:10.1016/S2213-2600(17)30268-0
16.
MalicLZhangPGYPlantPJ, et al. A machine learning and centrifugal microfluidics platform for bedside prediction of sepsis. Nat Commun. 2025;16(1):4442. doi:10.1038/s41467-025-59227-x
17.
MunroeESSpicerACastellvi-FontA, et al. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill. Lancet Respir Med. 2025;13(6):556-568. doi:10.1016/S2213-2600(25)00054-2
18.
WigerbladGWarnerSARamos-BenitezMJ, et al. Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. Sci Adv. 2023;9(1):eade8272. doi:10.1126/sciadv.ade8272
19.
StrichJRTianXSamourM, et al. Fostamatinib for the treatment of hospitalized adults with coronavirus disease 2019: a randomized trial. Clin Infect Dis. 2022;75(1):e491-e498. doi:10.1093/cid/ciab732
20.
MaitlandKKiguliSOpokaRO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364(26):2483-2495. doi:10.1056/NEJMoa1101549
